RenovoRx(RNXT) - 2025 Q1 - Quarterly Results

Exhibit 99.1 RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights Q1 2025 RenovoCath Revenues of ~$200,000, Exceeding Expectations and Anticipated to Continue Growing Sequentially with New Customer Purchase Orders and Reorders Cash on Hand of$14.6 Million Anticipated to Fully Fund both RenovoCath Commercialization Scale-up and Continued Progress Towards the Completion of the Ongoing Phase III TIGeR-PaC Clinical Trial Looking ahead, RenovoRx sees expansion opportunities across other ...